Background: Cryoprecipitate is used without knowing the concentration of coagulation factors it contains which poses danger of circulatory overload with no any improvement if several bags with low factor levels are transfused when the levels changes or drastically reduce. Objective: The objective was to evaluate gender influence on changes of Coagulation factors in cryoprecipitate plasma at Kisii Teaching and Referral Hospital. Methods: The study involved time series analysis design involving analysis of cryoprecipitate during storage at -18C for 5 weeks. Blood collected from the Kisii satellite blood transfusion center was received at Hematology laboratory where factor assays were performed on Erba Mannheim ECL 105 semi-automated coagulation analyzer. Thawing for subsequent coagulation factor analysis and serial testing was done using Stericox Plasma Thawing Bath at 37C, for 45 mins. Data were entered into Excel and analyzed by SPSS version 25. Results: The mean rank for cryoprecipitate from week one to week five was in a decreasing trend with 3.00, 1.99 and 1.01 respectively. This confirms a steady statistical significant difference in mean ranks for the time period. The coagulation factors in cryoprecipitate plasma in the donated blood were not affected by the gender of the blood donor. Conclusion: The gender of the donor has no effect on the coagulation factors in cryoprecipitate plasma

Background: Fresh frozen plasma is a critical substitute therapy in management of bleeding. Increased risk of venous thrombosis has been described to be associated with high plasma levels of several coagulation factors. Methodology: This study was a time series analysis of fresh frozen plasma stored at -18C for five weeks. A sample of 180 ml plasma was obtained from the blood centrifuged at 4000rpm which was aliquoted into three parts each containing 60ml. The first aliquot was used to assess the changes in coagulation factors in FFP at baseline during the first week of sample collection, the second aliquot was used to assess the changes in coagulation factors in FFP storage at -18C temp after three weeks of storage, the third aliquot was used to assess the changes in coagulation factors in FFP storage at -18C temp after five weeks of storage. Coagulation factor analysis was performed using Erba Mannheim ECL 105 coagulation analyzer, India factor results recorded. Thawing for subsequent coagulation factor analysis and serial testing of stored cryoprecipitate and fresh frozen plasma was done using Stericox Plasma Thawing Bath at 37C, for 45 mins before before analyzing the samples. Standard storage conditions for the aliquots were monitored and maintained to ensure homogeneity. Results: The findings showed significant changes in the coagulation factors in FFP during storage at -18 for a period to five weeks with chi-square value of 216.000 and asymptomatic significance value (p-value) <0.0001* less than the standard alpha 0.05. Conclusion: There was a constant decrease of coagulation factors in fresh frozen plasma during storage at -18C for 5 weeks at Kisii Teaching and Referral Hospital, Kisii County.

Background: Cryoprecipitate is used without knowing the concentration of coagulation factors it contains which might cause circulatory overload with no any improvement if several bags are transfused with low factor levels. Objective: The objective was to assess the changes in coagulation factors in cryoprecipitate plasma during storage at -18°C for 5 weeks at Kisii Teaching and Referral Hospital. Methods: The study involved time series analysis design involving analysis of cryoprecipitate during storage at -18°C for 5 weeks. Blood collected from the Kisii satellite blood transfusion center was received at Hematology laboratory where factor assays were performed on Erba Mannheim ECL 105 semi-automated coagulation analyzer. Thawing for subsequent coagulation factor analysis and serial testing was done using Stericox Plasma Thawing Bath at 37°C, for 45 mins. Data were entered into Excel and analyzed by SPSS version 25. Results: The mean rank for cryoprecipitate from week one to week five was in a decreasing trend with 3.00, 1.99 and 1.01 respectively. This confirms a steady statistical significant difference in mean ranks for the time period. Conclusion: There was a significant reduction in coagulation factors in cryoprecipitate plasma during storage at -18°C for 5 weeks at Kisii Teaching and Referral Hospital.